TRADING HALTED

Genetic Technologies Ltd GENE:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/01/21 EST
4.41UNCH (UNCH)
52 week range
1.41 - 10.30

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.41
  • 52 Week High10.30
  • 52 Week High Date07/15/20
  • 52 Week Low1.41
  • 52 Week Low Date03/23/20
  • Market Cap66.24M
  • Shares Out15.02M
  • 10 Day Average Volume1.30M
  • Dividend-
  • Dividend Yield-
  • Beta2.58
  • 1 Year % Change46.52

RATIOS/PROFITABILITY

  • EPS (TTM)-0.61
  • P/E (TTM)-7.20
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-4.893M
  • ROE (MRQ)-82.49%
  • Revenue (MRQ)10,000.00
  • Gross Margin (MRQ)-2,448.23%
  • Net Margin (MRQ)-61,792.61%
  • Debt To Equity (MRQ)3.70%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Genetic Technologies Ltd News

There is no recent news for this security.

Latest GENE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well...
Peter Rubenstein
Chairman
Simon Morriss
Chief Executive Officer
Stan Sack
Chief Operating Officer
Phillip Hains
Chief Financial Officer
Address
60-66 Hanover St, Fitzroy
Melbourne, VIC
3065
Australia